JUL 11, 2018 02:56 AM PDT

Blood Pressure Medication 'Verapamil' Stimulates Insulin Production

WRITTEN BY: Nouran Amin

A common blood pressure medication, verapamil, may improve outcomes for patients with Type 1 diabetes.

According to researchers at the University of Alabama (UAB) at Birmingham Comprehensive Diabetes Center, diabetes affects more than 30 million Americans. Now, research at UAB has led to the discovery of a "safe and effective novel therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent onset Type 1 diabetes."

Furthermore, verapamil, which is administered orally, will allow the patient's body to produce their very own insulin which limits the number of insulin injections needed.

"While this research is not an end-all cure for Type 1 diabetes, these findings are getting us closer to disease-altering therapies that can enable individuals with Type 1 diabetes to have more control over their disease and maintain some of their body's own insulin production," said Anath Shalev, director of UAB's CDC.

Published in Nature Medicine, the research team at UAB found a way to promote the patient's own beta cell function and insulin production.

When Shalev discovered that verapamil reversed the effects of Type 1 diabetes, human trials began.

Over a year, the clinical trials studied 24 patients between the ages of 18-45. 11 of these patients received the blood pressure medication and the other 13 received a placebo.

"Although this is a smaller sample group, our trial results give us promise that subjects with Type 1 diabetes have therapy options and that we are nearing a more effective way to deal with this disease," said Fernando Ovalle, director of UAB's Comprehensive Diabetes Clinic and co-principal investigator of the study. "Beyond verapamil allowing subjects with Type 1 diabetes the ability to live a life with less external insulin dependence, these findings will impact the quality of life that they can have."

By improving blood sugar control, patients suffering from Type 1 diabetes will experience fewer heart attacks, blindness, kidney disease and other issues.

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 20, 2019
Drug Discovery & Development
SEP 20, 2019
Aspirin Usage Improves Liver Function After Embolization Treatment
Aspirin usage has been under scrutiny in recent research. But now, studies are bringing aspirin therapy in renewed light with its association in improving ...
SEP 20, 2019
Drug Discovery & Development
SEP 20, 2019
Chemotherapeutics react differently to radiation
Patients with various types of cancer are almost always treated with a combination of chemotherapy and radiotherapy. In chemotherapy, therapeutics consist ...
SEP 20, 2019
Drug Discovery & Development
SEP 20, 2019
Can LSD Treat Addiction?
Modern medicine commonly refers to addiction as a brain disease caused by drugs and other negative stimuli. However, evidence is surmounting that addiction...
SEP 20, 2019
Drug Discovery & Development
SEP 20, 2019
Scientists Grow Mini Kidneys to Treat Kidney Disease
Current methods for testing potential treatments for kidney disease do not take genetic variation into account for how treatments may vary from patient to ...
SEP 20, 2019
Clinical & Molecular DX
SEP 20, 2019
Muscular Dystrophy Drug by Sarepta Therapeutics: Approval or Rejection by Drug Regulating Authorities?
Duchenne Muscular Dystrophy (DMD is a rare, genetic disorder that hampers muscle movement and is the most common pediatric muscular dystrophy. I...
SEP 20, 2019
Drug Discovery & Development
SEP 20, 2019
Does TruBrain Really Work?
TruBrain is a mix of different substances claimed to help people increase verbal fluency, avoid distractions, and boost their mental output. Created by a t...
Loading Comments...